Mode
Text Size
Log in / Sign up
N/A N=28 Health Services Research

Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study

Bipolar Disorder · Schizophrenia

Enrolled (actual)
28
Serious AEs
3.6%
Results posted
Jun 2017
Primary outcome: Primary: Positive Detection Accuracy — 94 percentage of observed ingestions

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Digital Health Feedback System (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Proteus Digital Health, Inc.
Primary completion
May 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Positive Detection Accuracy
94
SECONDARY
System Safety

Summary

Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia. Hypothesis: Using a digital health feedback system to characterize medication-taking behavior and activities of daily living is safe and tolerable in appropriately selected patients with bipolar disorder and schizophrenia.

Eligibility Criteria

Inclusion Criteria

  • Male or female ≥ 18 and ≤ 65 years of age
  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, by Structured Clinical Interview using DSM-IV SCID-I/P1, for either:

i. Bipolar disorder I, II, or Not Otherwise Specified (NOS), or ii. Schizophrenia or schizoaffective disorder

  • Clinical global impression scale-severity (CGI-S) of 3 or below
  • Currently on a stable regimen of oral antimanic or antipsychotic medication for at least 3 months
  • No anticipation to change or titrate the regimen in the next 28 days
  • Willingness to adhere to study procedures
  • Capacity to provide informed consent

Exclusion Criteria

  • Pregnancy, or women of child bearing potential who are not using a medically accepted means of contraception
  • Serious suicide or homicide risk, as assessed by evaluating clinician
  • Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
  • DSM-IV diagnoses or symptoms of substance use disorders, active within the last 60 days
  • A score of 3 or higher on the suspiciousness/paranoia item of the Brief Psychiatric Rating Scale (BPRS)
  • Acute, clinically significant gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, diarrhea, melena, or hematochezia
  • History of significant gastrointestinal disease or major gastrointestinal surgery
  • Clinical instability of any kind that, in the investigator's opinion, could preclude safe participation in the study
  • Known allergies that could preclude safe participation in the study
  • Current presence of an electronically active implanted medical device
  • Participation in another medical device study, or on any investigational drug or device within the last 30 days
  • Inability to obtain consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01804257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search